Info
A team leader and yet a self-motivated performer, ability to learn and contribute…
Aktivitäten
-
Proud to have contributed to the partnership between Innovent Biologics and Takeda, an important milestone in advancing our shared goal of delivering…
Proud to have contributed to the partnership between Innovent Biologics and Takeda, an important milestone in advancing our shared goal of delivering…
Beliebt bei Dr. Vivian Tian
-
Looking forward to joining Bio-Europe 2025 at Vienna. Informa Connect
Looking forward to joining Bio-Europe 2025 at Vienna. Informa Connect
Geteilt von Dr. Vivian Tian
-
📢 𝗧𝘂𝗯𝘂𝗹𝗶𝘀 𝗶𝘀 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 #𝗘𝗦𝗠𝗢𝟮𝟱! From October 17–21, our team will be in Berlin for this year’s ESMO Congress, ready to…
📢 𝗧𝘂𝗯𝘂𝗹𝗶𝘀 𝗶𝘀 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 #𝗘𝗦𝗠𝗢𝟮𝟱! From October 17–21, our team will be in Berlin for this year’s ESMO Congress, ready to…
Beliebt bei Dr. Vivian Tian
Berufserfahrung
Ausbildung
Weitere Aktivitäten von Dr. Vivian Tian
-
Recently I had shared AESC vision and its rapid growth story to graduates from Peking University, in this top institution of China on end of…
Recently I had shared AESC vision and its rapid growth story to graduates from Peking University, in this top institution of China on end of…
Beliebt bei Dr. Vivian Tian
-
🔔 🔔 🔔 DING DING DING!: Record financing of 308 million euros for m4-Award winner #Tubulis! ➡️ Read the full news: https://lnkd.in/emwtAEDj Great…
🔔 🔔 🔔 DING DING DING!: Record financing of 308 million euros for m4-Award winner #Tubulis! ➡️ Read the full news: https://lnkd.in/emwtAEDj Great…
Beliebt bei Dr. Vivian Tian
-
Hansoh Pharma announced an exciting new licensing agreement with Roche. Under the License Agreement, Hansoh shall grant Roche an exclusive, worldwide…
Hansoh Pharma announced an exciting new licensing agreement with Roche. Under the License Agreement, Hansoh shall grant Roche an exclusive, worldwide…
Beliebt bei Dr. Vivian Tian
-
# CD79b x CD3 bispecifics In the last 14 days, #USPTO published a patent application (US20250304679A1) on bispecific antibodies targeting CD79b—a B…
# CD79b x CD3 bispecifics In the last 14 days, #USPTO published a patent application (US20250304679A1) on bispecific antibodies targeting CD79b—a B…
Beliebt bei Dr. Vivian Tian
-
Today in partnership with Taiho Oncology, Inc., we are pleased to share results from the Phase 2b REZILIENT2 trial in patients with non-small cell…
Today in partnership with Taiho Oncology, Inc., we are pleased to share results from the Phase 2b REZILIENT2 trial in patients with non-small cell…
Beliebt bei Dr. Vivian Tian
-
We are excited to extend a warm welcome to Mark Selby as the newest member of our team, joining as Vice President, Head of Research!
We are excited to extend a warm welcome to Mark Selby as the newest member of our team, joining as Vice President, Head of Research!
Beliebt bei Dr. Vivian Tian
-
As Prostate Cancer Awareness Month comes to a close, we recognize the patients, families, caregivers, and advocates whose resilience inspires us…
As Prostate Cancer Awareness Month comes to a close, we recognize the patients, families, caregivers, and advocates whose resilience inspires us…
Beliebt bei Dr. Vivian Tian
-
ERS 2025 - That’s a wrap! On my way back from another great conference in Amsterdam. I really enjoyed learning about all the recent advances in…
ERS 2025 - That’s a wrap! On my way back from another great conference in Amsterdam. I really enjoyed learning about all the recent advances in…
Beliebt bei Dr. Vivian Tian
-
From cross-border deals to newcos, faster clinical data is fueling the China innovation story, turning biopharmas from Shanghai to Beijing into…
From cross-border deals to newcos, faster clinical data is fueling the China innovation story, turning biopharmas from Shanghai to Beijing into…
Beliebt bei Dr. Vivian Tian
-
Cancer is ever-evolving – that’s why our research must remain ahead of the curve. On #WorldCancerResearchDay, we reflect on perspectives from…
Cancer is ever-evolving – that’s why our research must remain ahead of the curve. On #WorldCancerResearchDay, we reflect on perspectives from…
Beliebt bei Dr. Vivian Tian
-
Jefferies congratulates Merus (NASDAQ:MRUS) on the Company’s $8.0 Billion sale to Genmab (CPSE:GMAB). We are honored to be serving as Financial…
Jefferies congratulates Merus (NASDAQ:MRUS) on the Company’s $8.0 Billion sale to Genmab (CPSE:GMAB). We are honored to be serving as Financial…
Beliebt bei Dr. Vivian Tian
-
“For millions of people, every breath is a battle and too often their struggle goes unseen.” Our CEO, Emma Walmsley has shared this…
“For millions of people, every breath is a battle and too often their struggle goes unseen.” Our CEO, Emma Walmsley has shared this…
Beliebt bei Dr. Vivian Tian